Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.8
(-0.48%)
CNY 20.8
(-0.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 607.02 Million CNY | 74.09% |
| 2022 | 348.68 Million CNY | 63.37% |
| 2021 | 213.43 Million CNY | 44.23% |
| 2020 | 147.98 Million CNY | 20.34% |
| 2019 | 122.96 Million CNY | -7.65% |
| 2018 | 133.15 Million CNY | 0.54% |
| 2017 | 132.43 Million CNY | -31.03% |
| 2016 | 192.01 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 629.74 Million CNY | 3.74% |
| 2024 Q3 | 1.42 Billion CNY | 88.74% |
| 2024 Q2 | 753.79 Million CNY | 19.7% |
| 2023 Q3 | 497.87 Million CNY | 22.11% |
| 2023 FY | 607.02 Million CNY | 74.09% |
| 2023 Q2 | 407.72 Million CNY | 10.65% |
| 2023 Q1 | 368.49 Million CNY | 5.68% |
| 2023 Q4 | 607.02 Million CNY | 21.92% |
| 2022 Q4 | 348.68 Million CNY | 65.83% |
| 2022 Q3 | 210.26 Million CNY | 1.59% |
| 2022 Q2 | 206.97 Million CNY | 14.44% |
| 2022 Q1 | 180.84 Million CNY | -15.27% |
| 2022 FY | 348.68 Million CNY | 63.37% |
| 2021 Q3 | 156.14 Million CNY | 8.24% |
| 2021 Q1 | 142.37 Million CNY | -3.79% |
| 2021 Q4 | 213.43 Million CNY | 36.69% |
| 2021 FY | 213.43 Million CNY | 44.23% |
| 2021 Q2 | 144.24 Million CNY | 1.31% |
| 2020 Q4 | 147.98 Million CNY | 9.05% |
| 2020 FY | 147.98 Million CNY | 20.34% |
| 2020 Q3 | 135.7 Million CNY | 13.94% |
| 2020 Q2 | 119.1 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q2 | 119.73 Million CNY | 0.0% |
| 2019 Q4 | 122.96 Million CNY | 0.0% |
| 2019 FY | 122.96 Million CNY | -7.65% |
| 2018 FY | 133.15 Million CNY | 0.54% |
| 2017 FY | 132.43 Million CNY | -31.03% |
| 2016 FY | 192.01 Million CNY | 0.0% |